Jeena Sikho Lifecare Ltd Q4 FY2024 Concall Summary

Key Takeaways

• Revenue surged 59% YoY, margin story accelerating: Revenue hit INR234 crores with EBITDA up 102% YoY to INR93 crores, lifting EBITDA margin to 29%. Profit margin reached 21%, up from 8% in FY22, as operating leverage kicked in on a largely fixed expense base.
• Occupancy is the central profit lever: With 1,270 beds at just 37% occupancy, management sees a direct line to 50% profit growth at 55% occupancy and a 3x profit jump at 80%, because hospitals break even from day one and carry no building capex.
• The model is pivoting hard to company-owned hospitals: 16 franchisees were cut in six months, with a plan to go to zero in 2-3 years, while 15 clinics will convert to hospitals this year. Management argues franchisees prioritize money over patients and underperform hired managers.
• OTC and insurance are the next growth engines: Cashless Ayush insurance went live 1 April, 15 companies are already on board, and 10 OTC formulas are slated to launch in 4-6 months at a 7x cost-to-retail markup.
• What to watch next quarter: Whether the promised occupancy jump from 37% to 55% materializes within three months, the pace of the 500-bed addition, and any concrete OTC launch dates.

The Occupancy-Driven Profit Flywheel

• Fixed costs, variable upside: Basic expenses are largely covered at current revenue, so each incremental occupied bed drops almost straight to profit. Management says profit grew 3.75x while turnover grew 2.2x, and targets PAT margin above 25% next year.
• Bed breakeven is instant: Hospitals are opened only where an existing clinic already draws 400+ patients per month, buildings are rented not owned, so new units are profitable from day one.
• Occupancy roadmap: From 37% today to a 55% target within three months, which management estimates would deliver roughly INR450 crores revenue. The FY26 target is 85% occupancy and INR600-650 crores revenue.
• Marketing shift to drive footfall: The company moved from outbound calling to informative video content and medical education, added TV channels (ABP News, Zee News), newspapers, and social media campaigns over the last seven months.

Manish Grover: "If my bed occupancy, I am telling you about my old bed. If it becomes 55%, then I will take a growth of 50%. If it becomes 80%, then I will be able to make my profit by 3 times."

Franchisee Phase-Out & Company-Owned Conversion

• 16 franchisees cut in six months: The remaining ~50 will go to zero within 2-3 years. Management's rationale: franchisees contribute no marketing or sales effort, behave as passive managers, and resist investment in patient well-being.
• The unit economics argument: A franchisee expects ~INR75,000 monthly return on a INR25 lakh investment, while the company can hire a manager for INR25,000-30,000 who performs better. Management claims the company was losing INR17 lakhs per franchisee versus simply earning bank interest on retained capital.
• Clinic-to-hospital conversion accelerating: At least 15 clinics will become hospitals this year, and the stated future plan is to eliminate clinics entirely in favor of an all-hospital model. Where conversions have happened, sales increased because hospital footfall rises.
• New hospital geographies: 5-6 hospitals planned in Uttar Pradesh (Meerut, Lucknow, Kanpur, Agra, Banaras, Saharanpur, plus a Noida search underway), and 3-4 hospitals targeted for Mumbai.

Manish Grover: "There is a challenge in working with a franchisee, sir. We think of the well-being of the patient, he only thinks of money."

OTC & Insurance: The Next Margin Layer

• OTC product pipeline: 10 formulas targeting diabetes, blood pressure, liver, kidney, and stress, priced INR150 to INR600, with the first five in CTRI approval. Launch window is 4-6 months. A dedicated OTC head was hired from Dr. Ortho / Kesh King.
• OTC pricing structure: Cost-to-retail markup of 7x minimum, split as 3.5x to the distribution chain (dealer, distributor, CNF), 1x to advertising, and 1x retained as roughly 15% margin.
• Cashless insurance tailwind: Ayush cashless treatment became effective 1 April, a first for Ayurveda under a government mandate. Last month brought INR2.5 crores from health insurance; 15 companies are already providing cashless treatment, and the company actively educates patients about their coverage.
• Shuddhi Sankalp subscription: Launched 2-3 months ago as an annual prepaid package with 25-30% discount, assigning each patient a dedicated doctor and agent for the year. Revenue is booked as treatment progresses, not upfront.

Manish Grover: "I think we will bring a profit of more than 25% next year because our expenses are being covered and what we are planning to bring in OTC will be an extra benefit."

Bed Expansion & Infrastructure Build-Out

• FY25 target: 500 beds added by 31 March 2025, taking total capacity from 1,270 to roughly 1,800. Phasing: 100 beds in 3 months, 300 within 6 months, remainder by year-end.
• Long-term cadence: 500-600 beds every year for the next five years, with a 3,000-bed target in three years and above 4,000 in five years. The ultimate ambition is 10,000 beds to become India's number one Ayurvedic healthcare company.
• Key upcoming facilities: A 100-bed dedicated infertility hospital within 3-4 months, a 350-bed hospital in Meerut, and 300 beds in Chandigarh within 4-5 months.
• New disease segments: Infertility and heart problems added to the existing focus on kidney failure, liver failure, and cancer.
• Expense centralization underway: A three-person team is centralizing India-wide purchasing; management targets a 3% monthly expense reduction, which would add roughly INR1 crore to monthly profit.

Governance, Accreditation & Market Upgrades

• Main board migration: The company will move from the SME board to the main board in FY25, likely around April when it completes three years since its 19 April IPO.
• NABH accreditation: Three new NABH hospitals received 15 April in Lucknow, Mumbai, and Meerut. An analyst flagged that the NABH website shows only 14 centers versus management's claim of 24; management attributed the gap to an outdated site and daycare centers not being listed.
• Big 4 appointment: Ernst & Young engaged for a management performance review for FY25, alongside a separate Delhi-based consultation firm.
• ESOP and retention: 1,30,000 shares issued to 738 employees (doctors and long-serving staff) on 16 March 2024, vesting over five years. Three cars were awarded to doctors, with 21 more announced for Diwali.
• Medical academy: Announced 20 days ago, tied up with Jeena Seekho and three colleges to train doctors and nurses, with the company retaining first right to recruit.

Overseas & Adjacent Bets

• International expansion: Nepal center inaugurated on the 15th; plans to open in at least three countries within two months, with Vietnam, Dubai, and Mauritius named. Management also visited Canada and London and met with an MSME organization spanning 112 countries where Ayurveda is approved.
• Wellness sector entry: Planning to start a wellness vertical, though no timeline was given.
• Clinical research pipeline: About 20 research papers in the pipeline, three active research programs, and a 100-bed clinical trial underway alongside medicine trials.
• M&A and tie-ups: Early-stage discussions on factories, products, and tie-ups in India and abroad, described as "first and second level" conversations with no committed timeline.

Guidance & Commitments

Key Metrics